Lexicon Pharmaceuticals (LXRX) presents a balance sheet as of March 31, 2026 with total assets of $268.8M and total liabilities of $66.0M, yielding book equity of $202.9M. Under a liquidation lens, the recovery picture is materially better than MFFAIS's stated CLV of -$27.9M due to a significant financing event and milestone receipts that have materially increased liquid assets since the prior annual filing. Cash and cash equivalents of $38.1M (100% recovery), short-term investments of $132.6M in U.S. Treasuries and corporate debt securities (estimated 98-99% recovery at fair value, minimal unrealized losses of $131K), and restricted cash of $29.0M (blocked account, 100% recovery but encumbered against the Oxford Term Loans covenant) together represent approximately $199.7M in liquid assets with near-par recoverable value. Against this, long-term debt of $49.7M (face value approximately $54.0M before unamortized discount of $4.3M) would be settled at face value in liquidation, not carrying value. Lease obligations total $8.0M present value ($11.2M undiscounted through 2034), which would not extinguish on wind-up. Operating lease right-of-use assets of $7.1M would receive a near-zero liquidation haircut as the underlying leases on office space (The Woodlands TX through 2031; Bridgewater NJ through 2034) carry no intrinsic value in a distressed wind-down. Goodwill of $44.5M carries zero liquidation value. PP&E net book value of $1.8M (computers, furniture, leasehold improvements) would recover 30-50 cents on the dollar, yielding approximately $0.5-$0.9M. Accounts receivable of $11.8M would recover at approximately 90-95%, or $10.6-$11.2M. Inventory of $0.3M at 60% recovery contributes negligibly. A $29.0M restricted cash balance is included in liquid assets but effectively pledged to the Oxford lender minimum cash covenant as of the balance sheet date; post-May 2026 refinancing via Hercules (not reflected on the March 31 balance sheet), this block is released. Contingent committed royalties ($4.5M for T1D approval) and milestone payment ($5.0M to Bristol-Myers Squibb upon pilavapadin Phase 3 dosing) are not accrued on the balance sheet but would crystallize in liquidation depending on regulatory outcomes. The approximate liquidation recovery to equity, netting $170M+ in liquid assets (after debt face-value settlement of ~$54M), operating lease obligations of $8.0M, and remaining current liabilities of $9.9M, yields a rough gross recovery of $95-$110M before wind-down costs, intangible zeroing, and senior claim settlement. This is substantially above the MFFAIS CLV of -$27.9M, reflecting the February 2026 equity raises ($96.5M net proceeds from common stock and Series B Preferred) and March-Q1 2026 Novo Nordisk milestone receipts ($20M recognized in Q1). The post-balance-sheet Hercules refinancing ($55M funded at close, Oxford fully repaid) is a material subsequent event not captured in the March 31 balance sheet but would shift the debt stack from ~$54M Oxford face value to ~$55M Hercules principal plus a 6.25% final payment ($3.4M) and prepayment fees, modestly increasing the liability at face. No pension obligations. No goodwill impairment disclosure. Filing does not separately XBRL-tag the Novo Nordisk milestone receivable or contingent obligations to BMS/Bristol-Myers Squibb.
▼ Community Notes